Sign In
Buy OCUL
$8.35
+0.0400 (+0.481%)
At Close: Jun 03, 2026
Ocular Therapeutix® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Tuesday, 04'th Jun 2024
BEDFORD, Mass., June 04, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company committed to enhancing people's vision and quality of life through
Ocular Therapeutix: Betting On Axpaxli For A Major Market Breakthrough
02:01pm, Monday, 03'rd Jun 2024
Ocular Therapeutix is a biopharmaceutical company with a successful commercial product, Dextenza, generating $57.9 million in revenue in 2023. The company's main value driver is Axpaxli, an axitinib i
Ocular Therapeutix: Unveiling Pipeline Progress (AXPAXLI, PAXTRAVA) And Q1 Results
05:30am, Saturday, 01'st Jun 2024
Ocular Therapeutix has provided promising updates on its clinical trials for Axpaxli and Paxtrava, utilizing its Elutyx drug-eluting platform. The company has appointed a new CEO and raised funds, ext
Ocular Therapeutix™ Reports First Quarter 2024 Results
04:05pm, Tuesday, 07'th May 2024
Recent Leadership Appointments Put Ocular on Track to Become a Leader in Retinal Care Site Activation and Patient Enrollment for AXPAXLI™ SOL-1 Phase 3 wet AMD Trial Progressing with First Subjects
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:16pm, Monday, 06'th May 2024
BEDFORD, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company committed to enhancing people's vision and quality of life through t
Ocular Therapeutix™ to Present at Two Upcoming Investor Conferences
07:30am, Monday, 06'th May 2024
BEDFORD, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to enhancing people's vision and quality
Ocular Therapeutix™ To Present at Two Ophthalmology Meetings, May 4-9, 2024
07:30am, Friday, 03'rd May 2024
2024 OIS Retina and ARVO meetings are being held in Seattle, Washington 2024 OIS Retina and ARVO meetings are being held in Seattle, Washington
Ocular Therapeutix™ to Host Investor Day in New York City on Thursday, June 13, 2024
07:30am, Wednesday, 01'st May 2024
First quarter 2024 financial results to be reported on Tuesday, May 7, 2024 Investor Day to replace first quarter 2024 earnings conference call; quarterly calls to resume regular cadence with second q
2 Small-Cap Growth Stocks With Room To Run
08:30am, Wednesday, 24'th Apr 2024
Small-cap stocks often rise in response to interest rate cuts. Archer Aviation and Ocular Therapeutix may be ideal candidates to buy ahead of this potential catalyst.
Ocular Therapeutix™ Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic Retinopathy
07:00am, Thursday, 18'th Apr 2024
46.2% of patients demonstrated a 1- or 2-step improvement in the Diabetic Retinopathy Severity Scale (DRSS) at 40 weeks in the AXPAXLI arm, compared to 0% in the control arm
The 3 Best Biotech Stocks to Buy Now: Q2 Edition
04:30pm, Tuesday, 16'th Apr 2024
Some of the hottest opportunities can be found in biotech stocks to buy now. With innovation, mergers and acquisitions, major companies looking to replenish their pipelines ahead of patent expirations
Biotech on a Budget: 7 Stocks Under $10 With Huge Potential
12:54pm, Monday, 15'th Apr 2024
The broader medical therapeutic sector is already volatile so it stands to reason in some sense to consider under-$10 biotech stocks. Imagine you acquired shares of a popular, richly priced enterprise
BEDFORD, Mass., April 15, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company committed to enhancing people's vision and quality of life through
Down -17.88% in 4 Weeks, Here's Why Ocular Therapeutix (OCUL) Looks Ripe for a Turnaround
10:36am, Tuesday, 09'th Apr 2024
Ocular Therapeutix (OCUL) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in
BEDFORD, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company committed to enhancing people's vision and quality of life through
